NeuroMetrix (NURO) Misses Q1 EPS by 5c

NeuroMetrix (NASDAQ: NURO) reported Q1 EPS of ($1.00), $0.05 worse than the analyst estimate of ($0.95). Revenue for the quarter came in at $2.28 million versus the consensus estimate of $2.65 million.

Business Outlook:

NeuroMetrix’ primary initiative for 2016 is to make Quell available at leading retailers. This effort started with the March announcement that Quell will be part of a digital health initiative at Target. The Company expects the retail expansion to continue during Q2 as discussions with other retailers mature into distribution arrangements. Promotion will support the retail launch. Television advertising was developed and tested during Q1 and will be part of an expanded media campaign. The Company believes that broad retail availability of Quell in locations where consumers shop for chronic pain solutions will positively impact Quell sales during 2016.

For earnings history and earnings-related data on NeuroMetrix (NURO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance